TW201028406A - 5-O-substituted 3-N-aryl-1,3,4-oxadiazolones for medical use - Google Patents

5-O-substituted 3-N-aryl-1,3,4-oxadiazolones for medical use Download PDF

Info

Publication number
TW201028406A
TW201028406A TW098144465A TW98144465A TW201028406A TW 201028406 A TW201028406 A TW 201028406A TW 098144465 A TW098144465 A TW 098144465A TW 98144465 A TW98144465 A TW 98144465A TW 201028406 A TW201028406 A TW 201028406A
Authority
TW
Taiwan
Prior art keywords
group
alkyl
aryl
crc6
substituted
Prior art date
Application number
TW098144465A
Other languages
English (en)
Chinese (zh)
Inventor
David Alexander Learmonth
Da Silva Patricio Manuel Vieira Araujo Soares
Original Assignee
Bial Portela & Ca Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bial Portela & Ca Sa filed Critical Bial Portela & Ca Sa
Publication of TW201028406A publication Critical patent/TW201028406A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/13—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW098144465A 2008-12-23 2009-12-23 5-O-substituted 3-N-aryl-1,3,4-oxadiazolones for medical use TW201028406A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20354908P 2008-12-23 2008-12-23

Publications (1)

Publication Number Publication Date
TW201028406A true TW201028406A (en) 2010-08-01

Family

ID=41722972

Family Applications (1)

Application Number Title Priority Date Filing Date
TW098144465A TW201028406A (en) 2008-12-23 2009-12-23 5-O-substituted 3-N-aryl-1,3,4-oxadiazolones for medical use

Country Status (3)

Country Link
AR (1) AR074978A1 (fr)
TW (1) TW201028406A (fr)
WO (1) WO2010074587A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130150346A1 (en) 2010-01-08 2013-06-13 Quest Ventures Ltd. Use of FAAH Inhibitors for Treating Parkinson's Disease and Restless Legs Syndrome
WO2011123719A2 (fr) 2010-03-31 2011-10-06 Ironwood Pharmaceuticals, Inc. Utilisation d'inhibiteurs de faah pour le traitement des douleurs abdominales, viscérales et pelviennes

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS531335B2 (fr) 1971-11-29 1978-01-18
US4076824A (en) 1975-02-03 1978-02-28 Rhone-Poulenc Industries Anthelmintic oxadiazolinone derivatives
FR2605007A2 (fr) * 1986-05-07 1988-04-15 Rhone Poulenc Agrochimie Herbicides de type sulfonyluree, leur preparation, les compositions les contenant et leur utilisation
US5236939A (en) 1989-09-23 1993-08-17 Bayer Aktiengesellschaft Substituted 1,3,4-oxa(thia)diazolinones process for their preparation and their use of combating endoparasites
DE3931843A1 (de) 1989-09-23 1991-04-04 Bayer Ag Substituierte 1,3,4-oxa(thia)diazolinone verfahren zu ihrer herstellung und ihre verwendung der bekaempfung von endoparasiten
DE19942354A1 (de) 1999-09-04 2001-03-08 Aventis Pharma Gmbh Substituierte 3-Phenyl-5-alkoxi-1,3,4-oxdiazol-2-one, ihre Herstellung und Verwendung in Arzneimitteln
NZ521207A (en) 2000-03-07 2005-04-29 Aventis Pharma Gmbh Substituted 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-one and use thereof for inhibiting hormone-sensitive lipase
AU2002347985A1 (en) 2001-11-15 2003-06-10 Eli Lilly And Company Peroxisome proliferator activated receptor alpha agonists
DE10208987A1 (de) 2002-02-28 2003-09-11 Aventis Pharma Gmbh Substituierte 3-Phenyl-5-alkoxi-1,3,4-oxidiazol-2-one, ihre Herstellung und Verwendung in Arzneistoffen
DE10208986A1 (de) * 2002-02-28 2003-09-11 Aventis Pharma Gmbh Verwendung substituierter 3-Phenyl-5-alkoxi-1,3,4-oxdiazol-2-one zur Herstellung von Arzneimitteln mit hemmender Wirkung an der pankreatischen Lipase
PL373329A1 (en) * 2002-07-12 2005-08-22 Sanofi-Aventis Deutschland Gmbh Heterocyclically substituted benzoylureas, method for their production and their use as medicaments
BRPI0821482A2 (pt) * 2007-12-27 2015-07-14 Bial Portela & Ca Sa 3-n-fenil-1,3,4-oxadiazolona 5-o-substituída, seu uso, sua composição e seu processo de preparação

Also Published As

Publication number Publication date
AR074978A1 (es) 2011-03-02
WO2010074587A3 (fr) 2010-11-11
WO2010074587A2 (fr) 2010-07-01

Similar Documents

Publication Publication Date Title
CN101903374B (zh) 作为met激酶抑制剂的2-苄基哒嗪酮衍生物
KR101099849B1 (ko) Ｍｅｋ의 헤테로시클릭 억제제 및 그의 사용 방법
CN101501028B (zh) 2-(杂环基苄基)哒嗪酮衍生物
CA2649924C (fr) Inhibiteurs de la c-fms kinase
US8211920B2 (en) 6-oxo-1,6-dihydropyridine derivatives as inhibitors of MEK and methods of use thereof
EP1998766A2 (fr) Composes indole utiles
CN101678214B (zh) 芳基醚哒嗪酮衍生物
US20110183981A1 (en) Heterocyclic inhibitors of mek and methods of use thereof
CN102066378B (zh) 作为MET激酶抑制剂的3-(3-嘧啶-2-基苄基)-1，2，4-三唑并[4，3-b]哒嗪衍生物
CN101326167A (zh) 用于治疗肿瘤的哒嗪酮衍生物
TW201030009A (en) Phosphoinositide 3-kinase inhibitors with a zinc binding moiety
CN102272125B (zh) 哒嗪酮衍生物
JP2010536719A (ja) ６−チオキソピリダジン誘導体
US20090075985A1 (en) Aryl sulfonamide peri-substituted bicyclics for occlusive artery disease
CN102015694A (zh) 哒嗪酮衍生物
JPH04210981A (ja) アザオキシインドール誘導体
TW200927729A (en) 4-heteroaryl-substituted phenoxyphenylacetic acid derivatives
TW201028406A (en) 5-O-substituted 3-N-aryl-1,3,4-oxadiazolones for medical use
CN102272112A (zh) 苯并噻唑酮衍生物
CN102256980A (zh) 3-(3-嘧啶-2-基苄基)-1，2，4-三唑并[4，3-b]嘧啶衍生物
JP2009530338A (ja) 可溶性アデニル酸シクラーゼのインヒビターとしてのインドール誘導体
CN102264742A (zh) 3-(3-嘧啶-2-基苄基)-1，2，4-三唑并[4，3-b]哒嗪衍生物
JP2009530339A (ja) 可溶性アデニル酸シクラーゼインヒビター
TW201100079A (en) 5-O-substituted 3-N-heteroaryl-1,3,4-oxadiazolones for medical use
TW200815347A (en) Inhibitors of soluble adenylate cyclase